Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
Omitting Frontline Chemotherapy Lowers Toxicity Without Sacrificing Survival in Oligometastatic Head and Neck Cancer
11/02/2023

Janelle Bradley

Janelle Bradley
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with...
11/02/2023
Oncology
News
Omitting Frontline Chemotherapy Lowers Toxicity Without Sacrificing Survival in Oligometastatic Head and Neck Cancer
11/02/2023

Janelle Bradley

Janelle Bradley
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with...
11/02/2023
Oncology

Advertisement

News
Toripalimab Approved for First-Line Treatment of Patients With Nasopharyngeal Carcinoma
10/31/2023
Allison Casey
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA...
10/31/2023
Oncology
News
Tipifarnib for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With HRAS Mutations
10/31/2023

Stephanie Holland 

Stephanie Holland 
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN...
10/31/2023
Oncology
News
Tipifarnib for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With HRAS Mutations
10/31/2023

Stephanie Holland 

Stephanie Holland 
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN...
10/31/2023
Oncology

Advertisement

News
Prolonged Survival with Cancer Vaccine Among Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
10/21/2023
Allison Casey
According to a phase 2b trial, the cancer vaccine MVX-ONCO-1 demonstrated a tolerable safety profile and clinically meaningful prolonged overall survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
According to a phase 2b trial, the cancer vaccine MVX-ONCO-1 demonstrated a tolerable safety profile and clinically meaningful prolonged overall survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
According to a phase 2b trial,...
10/21/2023
Oncology
News
Efficacy, Safety of Sacituzumab Govitecan Among Patients With Heavily Pretreated, Relapsed/Refractory Metastatic or Locally Advanced Head and Neck Squamous Cell Carcinoma
10/21/2023

Stephanie Holland

Stephanie Holland
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the...
10/21/2023
Oncology
News
No Benefit Adding Lapatinib to Chemoradiotherapy for Patients With Non-HPV Head and Neck Carcinoma
10/13/2023

Allison Casey 

Allison Casey 
In a phase 2 trial, the addition of dual EGFR-HER2 inhibitor lapatinib to chemoradiotherapy did not improve the survival outcomes among patients with non-HPV head and neck carcinoma.
In a phase 2 trial, the addition of dual EGFR-HER2 inhibitor lapatinib to chemoradiotherapy did not improve the survival outcomes among patients with non-HPV head and neck carcinoma.
In a phase 2 trial, the addition...
10/13/2023
Oncology

Advertisement

Tsz Lun Yeung, MD
Videos
Extended Dosing of Xevinapant Post-Radiotherapy Improved Efficacy in Preclinical Models of Head and Neck Cancer
07/18/2023

Featuring Tsz Lun Yeung, MD

Featuring Tsz Lun Yeung, MD
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting,...
07/18/2023
Oncology
News
Nivolumab Plus Ipilimumab vs Nivolumab Alone for Head and Neck Squamous Cell Carcinoma
04/27/2023
Allison Casey
In a phase 2 trial, patients with recurrent or metastatic head and neck squamous cell carcinoma did not derive a clinical benefit from nivolumab plus ipilimumab compared to nivolumab alone.
In a phase 2 trial, patients with recurrent or metastatic head and neck squamous cell carcinoma did not derive a clinical benefit from nivolumab plus ipilimumab compared to nivolumab alone.
In a phase 2 trial, patients...
04/27/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use